Takeda Pharmaceutical is negotiating the acquisition of Swiss drugmaker Nycomed for about $14 billion. Takeda has cash reserves of $10.8 billion and will be using this to fund the acquisition, as well as loans from banks. The strong yen has made acquisitions easier for Japanese companies. Takeda's Prevacid ulcer treatment and the Actos diabetes treatment have both expired. A generic launch of Actos is expected in August 2011. Takeda bought the U.S. unit of Millenium Pharmaceutical in 2008 for $8.9 billion for a significant presence in the oncology field. Takeda projects a drop in net profit by April 2013 by 35%, and sales by 11%, for the fiscal year 2013. Takeda's president says it will make investments in China of about 20-30 billon yen and target a ten fold increase in sales in China to 30 billion yen by 2015.